Skip to search formSkip to main contentSkip to account menu

Cerivastatin sodium

Known as: 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, monosodium salt, (S-(R*,S*-(E)))-, 7-(4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyrid-3-yl)-3,5-dihydroxy-6-heptenoate sodium salt, rivastatin 
The sodium salt of cerivastatin, a synthetic lipid-lowering agent.
National Institutes of Health

Related topics

Related topics

12 relations
CYP2C8 protein, humanCYP3A7 protein, humanCoronary Artery DiseaseDrug Allergy

Broader (1)

cerivastatin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Understanding Mass Tort Defendant Incentives for Confidential Settlements: Lessons from Bayer's Cerivastatin Litigation Strategy
Settlement agreements that require a plaintiff not to disclose or publicize any information about her claim are both common and… 
Review
2003
Review
2003
Rhabdomyolyse unter Cerivastatin-Monotherapie
ZusammenfassungCerivastatin wurde als ein reversibler HMGCoA- Reduktase-Hemmer (Statin) erfolgreich in der Behandlung der… 
2001
2001
Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia.
2001
2001
Tacrolimus/cerivastatin interaction study in liver transplant recipients.
With advances in immunosuppressive treatment, graft loss due to acute and chronic rejection has declined such that a variety of… 
Review
2001
Review
2001
[Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].
A 67-year-old man treated with gemfibrozil for a year development rhabdomyolysis and anuric renal failure after addition of… 
2001
2001
The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.
OBJECTIVE The single-dose and steady-state pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin and its two major… 
Highly Cited
1999
Highly Cited
1999
Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy.
Review
1998
Review
1998
Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition.
1997
1997
Reduction of Plasma Cholesterol Levels and Induction of Hepatic LDL Receptor by Cerivastatin Sodium (CAS 143201-11-0, BAY w 6228), a New Inhibitor of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase…
The effects of cerivastatin sodium (BAY w 6228), a new type of inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA… 
1995
1995
No Pharmacokinetic or Pharmacodynamic Interaction Between Rivastatin and Warfarin
Twenty‐one healthy, male volunteers completed this double‐blind, randomized, two‐period, crossover study to determine the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)